Literature DB >> 10725254

Factors influencing the low-frequency associated nicotinic ACh autoreceptor-mediated depression of ACh release from rat motor nerve terminals.

C Prior1, S Singh.   

Abstract

1. We have studied the inhibitory autoreceptor control of acetylcholine (ACh) release from rat motor nerve endings using an electrophysiological technique to quantify evoked ACh release in isolated hemidiaphragm muscles. Quantal ACh release (m) was estimated from the ratio of amplitudes of nerve evoked endplate currents and spontaneously occurring miniature endplate currents. 2. The nicotinic ACh receptor agonist cytisine (1 microM) decreased m at 0.5 Hz by around 20% but had no effect on m at 50 Hz. Changing the extracellular Ca(2+) concentration from 1.8 mM to either 0.45 or 3.6 mM abolished the effect of cytisine on m at 0.5 Hz. The nicotinic ACh receptor antagonist hexamethonium (200 microM) increased m at 0.5 Hz by 15 - 20%. 3. The effects of cytisine and hexamethonium on m at 0.5 Hz were blocked by 10 microM verapamil, which itself significantly increased m. However, the effects of cytisine and hexamethonium on m at 0.5 Hz were not sensitive to 10 microM of the calmodulin antagonist, W-7. This concentration of W-7 attenuates effects on ACh release mediated by facilitatory prejunctional nicotinic ACh autoreceptors. 4. Our present observations are suggestive of actions of cytisine and hexamethonium to activate and inhibit respectively negative-feedback prejunctional nicotinic ACh autoreceptors. Further, they strengthen the case for the existence of two separate and independent autoregulatory mechanisms for the control of ACh release from motor nerve terminals and give a preliminary insight into the cellular mechanism involved in the autoinhibition of ACh release.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10725254      PMCID: PMC1571942          DOI: 10.1038/sj.bjp.0703161

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

1.  Functional modulation of human "ganglionic-like" neuronal nicotinic acetylcholine receptors (nAChRs) by L-type calcium channel antagonists.

Authors:  D L Donnelly-Roberts; S P Arneric; J P Sullivan
Journal:  Biochem Biophys Res Commun       Date:  1995-08-15       Impact factor: 3.575

2.  Potentiation of nicotinic receptor response by external calcium in rat central neurons.

Authors:  C Mulle; C Léna; J P Changeux
Journal:  Neuron       Date:  1992-05       Impact factor: 17.173

Review 3.  Prejunctional actions of muscle relaxants: synaptic vesicles and transmitter mobilization as sites of action.

Authors:  C Prior; L Tian; J Dempster; I G Marshall
Journal:  Gen Pharmacol       Date:  1995-07

Review 4.  Electrophysiological analysis of transmission at the skeletal neuromuscular junction.

Authors:  C Prior; J Dempster; I G Marshall
Journal:  J Pharmacol Toxicol Methods       Date:  1993-09       Impact factor: 1.950

5.  Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes.

Authors:  L E Chavez-Noriega; J H Crona; M S Washburn; A Urrutia; K J Elliott; E C Johnson
Journal:  J Pharmacol Exp Ther       Date:  1997-01       Impact factor: 4.030

6.  Calcium channels involved in synaptic transmission at the mature and regenerating mouse neuromuscular junction.

Authors:  E Katz; P A Ferro; G Weisz; O D Uchitel
Journal:  J Physiol       Date:  1996-12-15       Impact factor: 5.182

7.  Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit.

Authors:  R L Papke; S F Heinemann
Journal:  Mol Pharmacol       Date:  1994-01       Impact factor: 4.436

8.  Comparison of neuronal nicotinic receptors in rat sympathetic neurones with subunit pairs expressed in Xenopus oocytes.

Authors:  P J Covernton; H Kojima; L G Sivilotti; A J Gibb; D Colquhoun
Journal:  J Physiol       Date:  1994-11-15       Impact factor: 5.182

9.  P-type voltage-dependent calcium channel mediates presynaptic calcium influx and transmitter release in mammalian synapses.

Authors:  O D Uchitel; D A Protti; V Sanchez; B D Cherksey; M Sugimori; R Llinás
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

10.  Nicotinic antagonist-produced frequency-dependent changes in acetylcholine release from rat motor nerve terminals.

Authors:  L Tian; C Prior; J Dempster; I G Marshall
Journal:  J Physiol       Date:  1994-05-01       Impact factor: 5.182

View more
  5 in total

1.  Postsynaptic production of nitric oxide implicated in long-term depression at the mature amphibian (Bufo marinus) neuromuscular junction.

Authors:  Sarah J Etherington; Alan W Everett
Journal:  J Physiol       Date:  2004-07-08       Impact factor: 5.182

2.  An electrophysiological study of muscarinic and nicotinic receptors of rat paratracheal ganglion neurons and their inhibition by Z-338.

Authors:  Yumiko Kanemoto; Hitoshi Ishibashi; Atsushi Doi; Norio Akaike; Yushi Ito
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

3.  Excitatory effect of acotiamide on rat and human bladder: Implications for underactive bladder treatment.

Authors:  Nishant Singh; Shinsuke Mizoguchi; Takahisa Suzuki; Irina Zabbarova; Youko Ikeda; Anthony Kanai; Christopher Chermansky; Naoki Yoshimura; Pradeep Tyagi
Journal:  Life Sci       Date:  2020-08-03       Impact factor: 5.037

4.  Presynaptic inhibition of spontaneous acetylcholine release induced by adenosine at the mouse neuromuscular junction.

Authors:  Silvana De Lorenzo; Mariela Veggetti; Salomón Muchnik; Adriana Losavio
Journal:  Br J Pharmacol       Date:  2004-04-05       Impact factor: 8.739

5.  The mechanism of choline-mediated inhibition of acetylcholine release in mouse motor synapses.

Authors:  A E Gaydukov; P O Bogacheva; E O Tarasova; O P Balezina
Journal:  Acta Naturae       Date:  2014-10       Impact factor: 1.845

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.